Skip to main content
Figure 5 | Orphanet Journal of Rare Diseases

Figure 5

From: Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis

Figure 5

Cysteamine disrupts production of normal human bronchial epithelial (NHBE) cell-derived mucus. Differentiated NHBE monolayers were exposed (basally) to 1 mg/ml cysteamine or control culture media for 7 days. Mucin production at the apical aspect was then assessed by Alcian blue staining macro- and microscopically (panels A & B) and the amount of free, non-mucin bound airway surface fluid quantified (panel C).

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172